Navegando por Palavras-chave "Autoimmune diseases"
Agora exibindo 1 - 9 de 9
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAssociation between demyelinating disease and autoimmune rheumatic disease in a pediatric population(Elsevier Science Inc, 2017) Amorim, Ana Luiza M. [UNIFESP]; Cabral, Nadia C. [UNIFESP]; Osaku, Fabiane M. [UNIFESP]; Len, Claudio A. [UNIFESP]; Oliveira, Enedina M. L. [UNIFESP]; Terreri, Maria Teresa [UNIFESP]Introduction: Multiple sclerosis (MS) and neuromyelitis optica (NMO) are demyelinating diseases of the central nervous system. Autoimmunity in patients with demyelinating disease and in their families has been broadly investigated and discussed. Recent studies show a higher incidence of rheumatic autoimmune diseases among adult patients with MS or NMO and their families, but there are no studies in the pediatric population. Objective: To evaluate an association of MS and NMO with autoimmune rheumatic diseases in pediatric patients. Method: 22 patients younger than 21 years old with MS or NMO diagnosed before the age of 18 years were evaluated regarding epidemiological data, clinical presentation, association with autoimmune diseases, family history of autoimmune diseases, laboratory findings, imaging studies and presence of auto-antibodies. Results: Among the patients studied, there was a prevalence of females (68.1%). The mean age of symptoms onset was 8 years and 9 months and the mean current age was 16 years and 4 months. Two patients (9%) had a history of associated autoimmune rheumatic disease: one case of juvenile dermatomyositis in a patient with NMO and another of systemic lupus erythematosus in a patient with MS. Three patients (13%) had a family history of autoimmunity in first-degree relatives. ANA was found positive in 80% of patients with NMO and 52% of patients with MS. About 15% of ANA-positive patients were diagnosed with rheumatologic autoimmune disieses. Conclusion: Among patients with demyelinating diseases diagnosed in childhood included in this study there was a high frequency of ANA positivity but a lower association with rheumatologic autoimmune diseases than that observed in studies conducted in adults. (C) 2016 Elsevier Editora Ltda.
- ItemAcesso aberto (Open Access)Auto-estima na forma inativa da oftalmopatia de Graves(Conselho Brasileiro de Oftalmologia, 2008-04-01) Magalhães, Carlos Henrique de Toledo [UNIFESP]; Pereira, Max Domingues [UNIFESP]; Manso, Paulo Góis [UNIFESP]; Veiga, Daniela Francescato [UNIFESP]; Novo, Neil Ferreira [UNIFESP]; Ferreira, Lydia Masako [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Universidade do Vale do Sapucaí Programa de Mestrado Interinstitucional; UNIVÁS Departamento de Oftalmologia; UNIVÁS Departamento de Cirurgia; UNIVÁS Departamentos de Bioestatística; UNIVÁS Programa de Mestrado InterinstitucionalPURPOSE: To assess the self-esteem of Graves' ophthalmopathy patients in the inactive phase. METHODS: Thirty euthyroid patients were evaluated in the inactive phase of disease with age ranging from 26 to 65 years, average of 43 ± 11,0 years, called study group and 39 individuals without Graves' ophthalmopathy with age ranging from 18 to 67 years, average of 41 ± 13,4 years, selected from the general population called control group. To evaluate the self-esteem the Rosenberg UNIFESP/EPM self-esteem scale, applied by means of an interview, was utilized. The self-esteem scores in the two studied groups were compared by means of the non-parametric Mann-Whitey test. The same test was applied to compare the obtained scores in the Graves' ophthalmopathy group considering disease severity. RESULTS: No alteration with statistical significance in Graves' ophthalmopathy patients' self-esteem was observed (P=0.057). The study group presented, on average, lower self-esteem values when compared with the control group. There was no difference of self-esteem mild and moderate-severe patients (P=0.2710). CONCLUSION: Graves' ophthalmopathy in the inactive phase did not affect the patients' self-esteem in the group studied.
- ItemAcesso aberto (Open Access)Autoimmune diseases in the TH17 era(Associação Brasileira de Divulgação Científica, 2009-06-01) Mesquita Júnior, Danilo [UNIFESP]; Cruvinel, Wilson de Melo [UNIFESP]; Câmara, Niels Olsen Saraiva [UNIFESP]; Kállas, E.g.; Andrade, Luiz Eduardo Coelho [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Universidade de São Paulo (USP); Universidade Católica de Goiás Departamento de BiomedicinaA new subtype of CD4+ T lymphocytes characterized by the production of interleukin 17, i.e., TH17 cells, has been recently described. This novel T cell subset is distinct from type 1 and type 2 T helper cells. The major feature of this subpopulation is to generate significant amounts of pro-inflammatory cytokines, therefore appearing to be critically involved in protection against infection caused by extracellular microorganisms, and in the pathogenesis of autoimmune diseases and allergy. The dynamic balance among subsets of T cells is important for the modulation of several steps of the immune response. Disturbances in this balance may cause a shift from normal immunologic physiology to the development of immune-mediated disorders. In autoimmune diseases, the fine balance between the proportion and degree of activation of the various T lymphocyte subsets can contribute to persistent undesirable inflammatory responses and tissue replacement by fibrosis. This review highlights the importance of TH17 cells in this process by providing an update on the biology of these cells and focusing on their biology and differentiation processes in the context of immune-mediated chronic inflammatory diseases.
- ItemAcesso aberto (Open Access)Como interpretar e valorizar adequadamente o teste de anticorpos antinúcleo(Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, 2007-06-01) Dellavance, Alessandra [UNIFESP]; Andrade, Luiz Eduardo Coelho [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Fleury Medicina Diagnóstica Setor de ImunologiaThe tradicional fluorescent antinuclear antibody test (ANA) has required constant update efforts from personel involved in performing and interpreting its results. The methodological advances have brought up a considerable improvement in the test s sensitivity and, consequentely, a decrease in its specificity. This has resulted in an increasing number of positive tests in apparently healthy subjects. However, there are some peculiar features associated with the auto-antibodies in patients with autoimmune diseases that are not present in those observed in healthy subjects. The objective of the present review is to bring an approach on the most important points to be considered in the analysis and evalution of an ANA test that might help in the identification of patients with autoimmune disease. Title and immunofluorescence pattern are discussed as important parameters and they are important in the evaluation of ANA and in the reflex demand for further tests for specific autoantibodies. The basic concepts of the National Consensus on Standardization of ANA-HEp-2 Report are posted. Finally, we explore the possible meanings of a positive ANA test in a patient without objective evidence of autoimmune disease.
- ItemAcesso aberto (Open Access)I Consenso Nacional para Padronização dos Laudos de FAN HEp-2(Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, 2002-07-01) Dellavance, Alessandra [UNIFESP]; Gabriel Júnior, Alexandre [UNIFESP]; Cintra, Alice Friedenberg de Ulhôa; Ximenes, Antônio Carlos; Nuccitelli, Barbara; Mühlen, Carlos Alberto Von; Bichara, Carlos David Araújo; Yano, Cristiane; Carvalho, Darlene Gonçalves; Bonfá, Eloisa Silva Dutra de Oliveira; Guimarães, Fabiana N.c.; Mundim, Hugo M.; Pfrimer, Irmtraut Araci Hoffmann; Rego, Jozelia; Andrade, Luiz Eduardo Coelho [UNIFESP]; Mesquita, Mauro Meira de; Santiago, Mittermayer Barreto; Silva, Nilzio Antonio; Miranda, Paulo J.; Leser, Paulo; Francescantonio, Paulo Luiz Carvalho; Jarach, Renata; Levy, Roger Abramino; Neves, Suzane Pretti Figueiredo; Cruvinel, Wilson de Melo [UNIFESP]; Santos, Wilton Silva dos [UNIFESP]; Laboratório Fleury; Centro Imuno Reumatológico de São Paulo; Biorad Diagnósticos; Universidade Federal de Goiás; Laboratório Clínico Padrão; Pontifícia Universidade Católica; Laboratório Amaral Costa; Universidade Católica de Goiás; Laboratório Pardini; Universidade de São Paulo (USP); Laboratório Exame; Universidade Federal de São Paulo (UNIFESP); EBMSP; Universidade Federal de Pernambuco; UERJ; Laboratório Labs; UFMG; Hospital de BaseThe technique of immunofluorescence using HEp-2 cells as substrate is the screening method of choice for the presence of autoantibodies in many clinical laboratories. The lack of a specific terminology for reporting results brings problems in quality control, clinical utility of the test, and standardization attempts. The first Brazilian Consensus for Standardization of ANA in HEp-2 Cells took place in Goiânia in August 2000. Several laboratory specialists with experience in the methodology showed up. They established guidelines for the description of ANA patterns in the Portuguese language, encompassing distinct descriptions for nuclear, nucleolar, cytoplasmic and mitotic apparatus patterns of fluorescence. Recommendations were also established regarding screening titers, final dilution titer, and on morphological criteria for reading the slides.
- ItemAcesso aberto (Open Access)Pioderma gangrenoso bolhoso e síndrome mielodisplásica(Sociedade Brasileira de Dermatologia, 2006-10-01) Batista, Mariana Dias [UNIFESP]; Fernandes, Ricardo Limongi [UNIFESP]; Rocha, Marco Alexandre Dias Da [UNIFESP]; Ikino, Juliana Kida [UNIFESP]; Pinheiro, Ronald Feitosa [UNIFESP]; Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]; Michalany, Nílceo Schwery [UNIFESP]; Almeida, Fernando Augusto De [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Pyoderma gangrenosum can present as a cutaneous manifestation of paraneoplastic syndromes. A case of bullous pyoderma gangrenosum associated with bicytopenia is described. During the complementary investigation, myelogram, bone marrow biopsy and karyotype were performed, and showed a pattern consistent with myelodysplastic syndrome. The patient was treated with dapsone with improvement. Pyoderma gangrenosum can be a manifestation of systemic diseases. The possibility of myelodysplastic syndrome should always be considered in patients with pyoderma gangrenosum associated with cytopenia. Pyoderma gangrenosum could indicate poorer prognosis in patients with systemic diseases.
- ItemAcesso aberto (Open Access)Repercussões imunológicas dos distúrbios do sono: o eixo hipotálamo-pituitária-adrenal como fator modulador(Associação Brasileira de Psiquiatria - ABP, 2007-05-01) Palma, Beatriz Duarte [UNIFESP]; Tiba, Paula Ayako [UNIFESP]; Machado, Ricardo Borges [UNIFESP]; Tufik, Sergio [UNIFESP]; Suchecki, Deborah [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)OBJECTIVE: To review the literature on the interaction between sleep and the immune system. METHOD: A search on Web of Science and Pubmed database including the keywords sleep, sleep deprivation, stress, hypothalamic-pituitary-adrenal axis, immune system, and autoimmune diseases. RESULTS: On Web of Science, 588 publications were retrieved; 61 references, more significant and closer to our objective, were used, including original articles and review papers. CONCLUSION: Sleep deprivation and immune system exert a bidirectional influence on each other. Since sleep deprivation is considered a stressor, inasmuch as it induces elevation of cortisol or corticosterone levels in humans and rodents, respectively, and given the well-known immunosuppressive effect of glucocorticoids, we propose that increased activation of the hypothalamic-pituitary-adrenal axis is a major mediator of the immune alterations observed in patients with insomnia or in sleep deprived subjects.
- ItemSomente MetadadadosTowards a better understanding of the clinical association of anti-DFS70 autoantibodies(Elsevier Science Bv, 2016) Mahler, Michael; Meroni, Pier Luigi; Andrade, Luis E. [UNIFESP]; Khamashta, Munther; Bizzaro, Nicola; Casiano, Carlos A.; Fritzler, Marvin J.Anti-DFS70 antibodies and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies (ANA), especially when present at high titres, anti-DFS70 antibodies are not prevalent in ANA associated rheumatic diseases. Despite significant interest and progress in understanding the clinical association of anti-DFS70 antibodies, no specific clinical associations have been confirmed. In reality, several studies reporting clinical association of these antibodies (i.e. atopic dermatitis, thrombosis, autoimmune thyroiditis) have added confusion instead of bringing significant insight. In addition, several groups have consistently reported on the occurrence of anti-DFS70 antibodies in a relevant fraction of apparently healthy individuals. This review aims to analyse the current knowledge and to provide future guidance to analyse potential clinical associations of anti-DFS70 antibodies by summarizing and interpreting recent findings. (C) 2015 Elsevier B.V. All rights reserved.
- ItemSomente MetadadadosTowards a better understanding of the clinical association of anti-DFS70 autoantibodies(Elsevier Science Bv, 2016) Mahler, Michael; Meroni, Pier Luigi; Andrade, Luis E. [UNIFESP]; Khamashta, Munther; Bizzaro, Nicola; Casiano, Carlos A.; Fritzler, Marvin J.Anti-DFS70 antibodies and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies (ANA), especially when present at high titres, anti-DFS70 antibodies are not prevalent in ANA associated rheumatic diseases. Despite significant interest and progress in understanding the clinical association of anti-DFS70 antibodies, no specific clinical associations have been confirmed. In reality, several studies reporting clinical association of these antibodies (i.e. atopic dermatitis, thrombosis, autoimmune thyroiditis) have added confusion instead of bringing significant insight. In addition, several groups have consistently reported on the occurrence of anti-DFS70 antibodies in a relevant fraction of apparently healthy individuals. This review aims to analyse the current knowledge and to provide future guidance to analyse potential clinical associations of anti-DFS70 antibodies by summarizing and interpreting recent findings. (C) 2015 Elsevier B.V. All rights reserved.